BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability of the mRNA-based individualized neoantigen specific immunotherapy (iNeST) autogene cevumeran (also known as BNT122, RO7198457) in combination with anti-PD-L1 immune checkpoint inhibitor atezolizumab and chemotherapy in patients with resected pancreatic ductal adenocarcinoma (PDAC).
Positive Phase 1 data from mRNA-based individualized neoantigen specific immunotherapy in patients with resected pancreatic cancer
June 9, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022